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Background: Clinically, multidrug-resistant Acinetobacter baumannii (MDR-AB) recurrence is
found in some patients although identified as successfully eradicated. We aim to discover
the characteristics of patients with MDR-AB recurrence in the respiratory tract.
Methods:We retrospectively collected 106 chronic respiratory failure patients with MDR-AB
harvest in pulmonary secretion culture.
Results: MDR-AB was successfully eradicated in 69 patients. Diabetes mellitus (p ¼ 0.030,
odds ratio [OR]: 2.7, 95% confidence interval [CI]: 1.1e6.4) and acute respiratory distress
syndrome (p ¼ 0.001, OR ¼ 4.8, 95% CI: 1.8e12.7) reduce the MDR-AB eradication rate. Be-
sides, a classification of colonization or infection was made beyond the 69 MDR-AB erad-
icated patients. In the colonization group, diabetes mellitus (p ¼ 0.009; OR ¼ 5.1, 95% CI: 1.5
e17.6) is the only independent factor to increase the recurrence rate. Glycated hemoglobin
level is also analyzed for each group to investigate diabetes control effect, but no significant
difference found.
Conclusions: Diabetes mellitus is a risk factor of MDR-AB recurrence among MDR-AB-
colonized patients; the impact of localized pneumonia patch in MDR-AB-infected pa-
tients requires further study to be clarified.cal Care Medicine, Kaohsiung Chang Gung Memorial Hospital, 123, Dapi Rd., Niaosong Dist.,
ext. 8199; fax: þ886 7 7322402.
w (A.-S. Lin).
g Gung University.
ublishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND
/by-nc-nd/4.0/).
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Scientific background of the subject
The recurrence of multidrug-resistant A. baumannii
(MDR-AB) after treatment is often seen, and it causes a
great medical waste in medical centers.
What this study adds to the field
To discover the risk factors of MDR-AB recurrence gives
assistance to future disease control policy formulation.
Besides, the information may contribute in early detec-
tion of MDR-AB recurrence and thus preventing possible
outbreaks.Multidrug-resistant A. baumannii (MDR-AB) emerges as a
cause of numerous global outbreaks via its strong adaptation
[1e3], and it admittedly causes a considerable medical waste
in most medical centers. The mechanisms of drug resistance
acquisition in A. baumannii include obtaining mobile genetic
elements, such as plasmids, transposons, or integrons from
the surrounding [4e7]. Series of literatures contribute to the
microbial agent selection against MDR-AB, including inhaled
or intravenous colistin methanesulfonate, Sulbactam, or
tigecycline [8e11]; However, few articles trace the disease
after cured.
In clinical practice, recurrent MDR-AB respiratory tract
acquisition is found in some cases although they are declared
MDR-AB is successfully eradicated. The recurrent isolateseasily
cause an outbreak and threaten the critically ill hospitalized
patients if not detected [12]. We suppose the risk factors of
MDR-AB recurrence exist, and recognizing these risk factors is a
benefit in clarifying the patients prone toMDR-AB recurrence.A
new disease control policy may be established to detect early
and control the recurrent MDR-AB. The purpose of this study is
to discover the risk factors of pulmonaryMDR-AB recurrence in
chronic respiratory failurepatients after successful eradication.Methods
Setting and study population
Kaohsiung Chang Gung Memorial Hospital is a 2500-bed
Teaching Medical Center in Southern Taiwan, and the Respi-
ratory Care Center (RCC) is a stepwise weaning unit accumu-
lating patients under ventilator dependence more than 21
days. Most of the patients come from internal medical, car-
diologic, surgical, or neurological intensive care units. One
who fails to wean his ventilator in 42 days after admitted to
RCCwill be transferred to out-hospital chronic facilities, or our
ordinary wards, or even back to intensive care unit. The
transferring indication is based onpatients'medical condition.
Thepatients in theRCC inKaohsiungChangGungMemorial
Hospital between June 1, 2009, and December 31, 2011, were
enrolled.Asweknow, there are someMDR-ABoutbreaks in theperiod. The laboratory profile ismore complete in the period as
well. The inclusion criteria include age over 18 years old and
harvested with MDR-AB in pulmonary secretions culture be-
tween June 1, 2009, and December 31, 2011. The exclusion
criteria were patients without tracheal intubation or trache-
ostomy,without antibiotics therapy, withMDR-AB bacteremia
or wound infection (either surgical or nonsurgical), and prior
MDR-AB acquisition before the data collection.
Definition
MDR-AB is defined to be insusceptible to all of the following
classes of antimicrobials: Aminoglycosides, antipseudomonal
carbapenems, antipseudomonal fluoroquinolones, anti-
pseudomonal penicillins, carbapenems, monobactams, quin-
olones, aminoglycosides, tetracycline, or trimethoprim/
sulfamethoxazole [13,14]. Acute respiratory distress syn-
drome (ARDS) is defined as arterial oxygen tension to fraction
of inspired oxygen ratio less than 200 [15].
The term “chronic respiratory failure” is defined as venti-
lator use more than 21 days, and the term “successful eradi-
cation” complies with our hospital's disease control and
prevention policy that two sets of pulmonary secretion spec-
imens in a row yield no MDR-AB in culture examinations. All
the specimens should be specified for “MDR-AB detection”,
and the secretion quality should be approved by our labora-
tory inspector. Unqualified specimens, e.g., saliva-
contaminated, are not counted. Once the MDR-AB is not
eradicated in 4 weeks after antibiotics initiation, the treat-
ment fails.
If the patients received aerosolized colistin therapy only,
we sorted these patients into “colonization group”. On the
other hand, people are identified as “infection group” if they
received any kinds of intravenous anti-MDR-AB antibiotics.
This classification matches with the conventional manage-
ment for MDR-AB pulmonary acquisition in our hospital. The
patient's sputum culture is traced for 1 month after successful
eradication. If one or more sets of sputum culture harvesting
MDR-AB during the first 1 month, we define that MDR-AB
recurs.
Study design
We recorded each patient's MDR-AB culture harvesting date,
antibiotics initiation date, MDR-AB successful eradication
date, MDR-AB recurrence date, and antibiotics duration;
meanwhile, the interval betweenMDR-AB cultures harvesting
date to the antibiotics initiation date is calculated.
We also collected the patients' basic information (age,
gender, cigarette smoking history, and alcohol drinking
history), comorbidities (diabetes mellitus, hypertension,
coronary artery disease, chronic kidney disease (CKD), liver
cirrhosis, chronic obstructive pulmonary disease, cerebral
vascular accident, and cancer history), clinical features
(ear temperature, pulse rate, respiration rate, blood pres-
sure, fraction of inspiration oxygen, and ventilator days
prior to MDR-AB treatment), and laboratory exam data
(hemogram, blood gas analysis profiles, C-reactive protein,
blood creatine level, sodium, and potassium). In addition,
patients' disease severity was measured in Acute
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(APACHE II) [16].
Initially, we compared the variables to look for the factors
affecting MDR-AB eradication. A categorization was made on
the MDR-AB-eradicated patients into colonization groups and
infection groups. The variables were then analyzed to
discover the risk factors of MDR-AB recurrence in each group
(overall, colonization, and infection group).
The sputum culture examination afterMDR-AB eradication
is not a routine check-up, and we re-examine the sputum if
any sign of airway infection (e.g., fever, radiologic patch, or
purulent sputum). Our RCC patients may be transferred to
respiratory care wards, kinds of chronic facilities adopting
long-term ventilated patients, if they fail to wean the venti-
lators. For these patients, we can obtain their sputum spec-
imen if they are brought back to our emergency depart to treat
upper airway infection.
Owing to the finding of the diabetes's influence to MDR-AB
recurrence, a secondary investigation of diabetes control is
performed via analyzing glycated hemoglobin (HbA1c) level
on each group. We calculated the HbA1c receiver operating
characteristic (ROC) curve to find the cut-off point, and then a
comparison between better sugar control and worsen control
was made.
Statistical analysis
Variables were analyzed with Chi-square test, Fisher's exact
test, Student's t-test, or the ManneWhitney U-test. Contin-
uous, normally distributed variables were presented as meanFig. 1 e Multidrug-resistant Acinetobacter baumannii was successfu
these patients into colonization or infection group.(standard deviation), whereas non-normally distributed vari-
ables were presented as median (interquartile range). Vari-
ables with p < 0.05 in univariate analysis were included into a
multivariate logistic regression.
Ethics
This is a retrospective study, and the study protocol was
approved by the Chang GungMedical Foundation Institutional
Review Board (Project No. 103-4706B).Results
From June 1, 2009, to December 31, 2011, we enrolled 295 pa-
tients with MDR-AB harvest in pulmonary secretion culture
examination. After filtered with exclusion criteria, 106 pa-
tients remained and 69 (65.1%) among these patients were
MDR-AB successfully eradicated [Fig. 1]. Of the variables
compared, diabetes mellitus (51% vs. 30.4%, p ¼ 0.034) and
ARDS (43.2% vs. 14.5%, p ¼ 0.001) are the two factors to reduce
the MDR-AB eradication rate. The p-values of both variables in
multivariable analysis are <0.05 (diabetes: OR: 2.7, 95% CI:
1.1e6.4; ARDS OR: 4.8, 95% CI: 1.8e12.7) [Table 1]. There is no
significant difference in APACHE II scores between the treat-
ment failure group and the successful eradication group.
MDR-AB recurred in 18 (26.1%) patients after 1 month
[Table 2]; we analyzed the MDR-AB recurrence risk factors in 3
groups (overall patient group, MDR-AB colonization group,
and MDR-AB infection group). For the overall MDR-ABlly eradicated in 69 patients and a categorization is made on
Table 1 e Baseline factors to eradicate multidrug-resistant Acinetobacter baumannii.
Variables Without eradication
(n ¼ 37)
Eradication
(n ¼ 69)
Univariate
analysis P
Multivariate
analysis P
OR
(95% CI)
Age, mean (SD) 76.0 (10.9) 71.4 (14.0) 0.085
Gender (male), n (%) 21 (56.8) 40 (58.0) 0.904
APACHE II, median (IQR)a 20 (18.5e21) 20 (17e23) 0.839
Comorbidities
Diabetes, n (%) 19 (51.4) 21 (30.4) 0.034 0.030 2.7 (1.1e6.4)
Hypertension, n (%) 22 (59.5) 42 (60.9) 0.887
Coronary artery disease, n (%) 6 (16.2) 15 (21.7) 0.496
Chronic kidney disease, n (%) 6 (16.2) 14 (20.3) 0.609
Liver cirrhosis, n (%) 3 (8.1) 1 (1.4) 0.121
COPD, n (%) 8 (21.6) 12 (17.4) 0.596
Cerebral vascular accident, n (%) 7 (18.9) 21 (30.4) 0.200
Cancer, n (%) 5 (13.5) 14 (20.3) 0.386
Past histories
Cigarette smoking, n (%) 6 (16.2) 12 (17.4) 0.878
Alcohol drinking, n (%) 3 (8.1) 6 (8.7) 1.000
Pulmonary TB history, n (%) 2 (5.4) 6 (8.7) 0.710
Laboratory profiles
WBC, median (IQR) 11,300 (9150e17,400) 11,200 (8500e14,750) 0.327
Hematocrit, mean (SD) 31.0 (4.6) 30.4 (4.7) 0.537
Creatine, median (IQR) 0.77 (0.60e2.09) 0.86 (0.55e2.12) 0.866
C-reactive protein, median (IQR) 59.6 (25.0e88.2) 60.1 (34.0e141.2) 0.276
Clinical profiles
Blood pH, mean (SD) 7.44 (0.07) 7.44 (0.07) 0.940
FiO2 (%), median (IQR) 40 (35e40) 40 (32.5e40) 0.308
PaO2/FiO2 < 200, n (%) 16 (43.2) 10 (14.5) 0.001 0.001 4.8 (1.8e12.7)
Glasgow Coma Scale, median (IQR) 10 (3e11) 9.5 (3e11) 0.537
Shock, n (%) 12 (32.4) 13 (18.8) 0.116
Radiology
Localized patch, n (%)b 26 (70.3) 41 (59.4) 0.270
Abbreviations: SD: Standard deviation; IQR: Interquartile range; APACHE II: Acute Physiology and Chronic Health Evaluation scoring system;
COPD: Chronic obstructive pulmonary disease; TB: Tuberculosis; WBC:White blood cell; OR: Odds ratio; CI: Confidence interval; FiO2: Fraction of
inspired oxygen.
a APACHE II score was measured on days of first pulmonary sputum collection.
b The radiologic character of localized patch is determined by at least one licensed chest or radiology doctor.
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p ¼ 0.009, OR [95% CI]: 5.1 [1.5e17.6]) and localized pneumonia
patch (51.0% vs. 88.9%, p ¼ 0.012, OR [95% CI]: 8.2 [1.6e42.2])
were the two recurrence risk factors. Among the colonization
group, diabetes (14.3% vs. 50.0%, p ¼ 0.017) and ARDS (5.7% vs.
30.0%, p ¼ 0.031) show a significant difference in univariate
analysis [Table 3]. Both diabetes and ARDS were included into
amultivariate logistic regression, and themultivariate p-value
of diabetes and ARDS are 0.039 and 0.085, respectively. Dia-
betes becomes the only independent risk factor (p ¼ 0.039;
OR¼ 5.6, 95%CI: 1.09e29.03). As regards to the infection group,
localized patch (50% vs. 100%, p ¼ 0.022) passes the 0.05
threshold in univariate p-value [Table 3].
A secondary investigation of HbA1c is performed in each
study group. A total of 29 and 16 pieces of HbA1c data are ob-
tained in the raw eligible patients (diabetes number: 40) and
successful eradication patients (diabetes number: 21). The
HbA1c ROC curve is analyzed in both the overall group and the
MDR-AB colonization group. Of the overall group, the cut-off
point is 7.0 and the area under the curve (AUC) is 0.73. Never-
theless, HbA1c < 7.0 (n ¼ 7) and HbA1c > 7.0 (n ¼ 9) make no
significant differences in respect to MDR-AB recurrence (25.0%
vs. 62.5%, p ¼ 0.315). There are only seven piece of data ob-
tained in the colonization group; more case numbers arerequired for further analysis in this sub-group. The informa-
tionof antibiotics selection in eachgroup is provided inTable 4.Discussion
Acinetobacter baumannii is a Gram-negative coccobacillus and
tolerates long periods in both moist and dry conditions [2,3],
and the easy acquisition of drug resistance makes it a great
challenge in disease control. A. baumannii has become a lead-
ing cause of nosocomial pneumonia and bacteremia globally
[17,18]; Nevertheless, some people doubt its clinical influence
on morbidity and mortality. Recent studies began to associate
A. baumannii to increased mortality and prolonged intensive
care unit days [19,20]. Falagas et al. conducted a nine-study
systematic review and demonstrate the relationship between
A. baumannii and increased mortality [21]. He advocates that
clinicians should make every effort to combat them. In fact,
physicians have invested much investigation in A. baumannii
opposition, including antimicrobial agent selection and anti-
infection measures such as contact precautions, meticulous
environmental decontamination, hand washing, or even
chlorhexidine baths [8e12,22,23]. MDR-AB sometimes recurs in
respiratory tract even after successful eradication, and the
Table 2 e Recurrence for the overall MDR-AB-eradicated patients.
Variables Without recurrence
(n ¼ 51)
Recurrence
(n ¼ 18)
Univariate
analysis P
Multivariate
analysis P
OR
(95% CI)
Age, mean (SD) 70.7 (15.1) 73.7 (10.1) 0.603
Gender (male), n (%) 31 (60.8) 9 (50.0) 0.426
APACHE II, median (IQR) 20 (16e23) 21 (18e24) 0.195
Chronic comorbidities
Diabetes, n (%) 11 (21.6) 10 (55.6) 0.007 0.009 5.1 (1.5e17.6)
Hypertension, n (%) 29 (56.9) 13 (72.2) 0.251
Coronary artery disease, n (%) 12 (23.5) 3 (16.7) 0.743
Chronic kidney disease, n (%) 10 (19.6) 4 (22.2) 1.000
Liver cirrhosis, n (%) 0 (0.0) 1 (5.6) 0.261
COPD, n (%) 10 (19.6) 2 (11.1) 0.718
Cerebral vascular accident, n (%) 13 (25.5) 8 (44.4) 0.133
Cancer, n (%) 11 (21.6) 3 (16.7) 0.747
Past histories
Cigarette smoking, n (%) 10 (19.6) 2 (11.1) 0.718
Alcohol drinking, n (%) 4 (7.8) 2 (11.1) 0.647
Pulmonary TB history, n (%) 6 (11.8) 0 (0.0) 0.328
Laboratory profiles
WBC, median (IQR) 10,500 (8300e14,100) 11,650 (9000e17,050) 0.224
Hematocrit, mean (SD) 30.3 (4.7) 30.8 (5.0) 0.703
Creatine, median (IQR) 0.86 (0.59e1.82) 1.05 (0.46e3.60) 0.989
C-reactive protein, median (IQR) 59.5 (29.0e139.5) 79.9 (37.0e205.5) 0.557
Clinical profiles
Blood pH, mean (SD) 7.44 (0.07) 7.43 (0.10) 0.563
FiO2, median (IQR) (%) 35 (35e40) 40 (35e40) 0.554
PaO2/FiO2 < 200, n (%) 5 (11.1) 5 (20.8) 0.113
Glasgow Coma Scale, median (IQR) 10 (7e10) 9.5 (7.5e11) 0.631
Shock, n (%) 10 (20.0) 3 (16.7) 0.784
Radiologic characteristics
Localized patch, n (%) 26 (51.0) 16 (88.9) 0.005 0.012 8.2 (1.6e42.2)
Treatment
Days from culture positive to
antibiotics initiation, median (IQR)
3 (2e6) 3 (3e4) 0.743
Antibiotics duration, median (IQR) 11 (9e14) 9.5 (6.75e19) 0.929
Abbreviations: MDR-AB: Multidrug-resistant Acinetobacter baumannii; SD: Standard deviation; IQR: Interquartile range; APACHE II: Acute Phys-
iology and Chronic Health Evaluation scoring system; COPD: Chronic obstructive pulmonary disease; TB: Tuberculosis; WBC: White blood cell;
FiO2: Fraction of inspired oxygen; OR: Odds ratio; CI: Confidence interval.
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they easily cause cross-contamination before detected.
This article investigated the risk factors of MDR-AB recur-
rence. We excluded patients without tracheal intubation or
tracheostomy to make sure the entire specimens were
collected from pulmonary secretion rather than saliva, and
thus increasing the reliability of the microbial culture exam-
ination result. People with MDR-AB bacteremia or wound
infection are excluded to confirm the recurrent MDR-AB iso-
lates not related to systemic spreading. Although 65.1% people
are MDR-AB eradicated, 26.1% develop MDR-AB re-acquisition
after 1 month.
In addition, diabetes mellitus and ARDS are the two factors
reducing MDR-AB eradication rate in our study. ARDS can be
interpreted to be a more severe infectious status, and it is
reasonable to have a lower cure rate. As regard to diabetes, we
interestingly found that diabetes is a risk factor of treatment
failure as well to the MDR-AB recurrence (either the overall
patient group or the MDR-AB colonization group). Our hy-
pothesis is that diabetes mellitus interferes with our immune
system and raise difficulties in pathogen eradication. Previous
studies have discovered the dysfunctions of diabetic poly-
morphonuclear cells and diabetic monocytes/macrophages inchemotaxis, phagocytosis, and killing [24]. The declined A.
baumannii population after antimicrobial agent therapy may
not be totally eliminated but causing false-positive result in
eradication. The residual MDR-AB pathogen re-grows after
antibiotic treatment suspension. A multicenter caseecontrol
study in Korea shows that diabetes mellitus is independently
associated with hospital-acquired pneumonia caused by
carbapenem-resistant Gram-negative bacteria. In this study,
A. baumannii is the major pathogens of hospital-acquired
pneumonia and accounted for 72.1% of the total
carbapenem-resistant Gram-negative bacteria isolates [25].
This Korea study may drop a hint of a possible relation be-
tween diabetes and higher MDR-AB pneumonia incidence.
Nevertheless, the influence of diabetes vanishes (17.1% vs.
62.6%, p ¼ 0.235) when we focus on the MDR-AB infection
group. Our explanation is that people in the infection group
received intravenous anti-MDR-AB agents rather than aero-
solized colistin only; the antibiotics selection may somehow
affect the clearance of MDR-AB. The higher clear effect may
lower the residual MDR-AB and overshadow the diabetes
influence.
Localized pneumonia patch in the chest plain film is
another risk factor of MDR-AB recurrence in the overall
Table 3 e MDR-AB recurrence for colonization group and infection group.
Variables Without recurrence
(n ¼ 35, 16)a
Recurrence
(n ¼ 10, 8)b
Univariate
analysis P
Multivariate
analysis P
OR (95% CI)d
Age, mean (SD)
Colonization 72.0 (13.7) 72.4 (10.7) 0.932
Infection 67.7 (17.9) 75.3 (9.8) 0.279
Gender (male), n (%)
Colonization 22 (62.9) 7 (70.0) 0.677
Infection 9 (56.3) 2 (25.0) 0.156
APACHE II, median (IQR)
Colonization 20 (15e23) 19.5 (18e22) 0.935
Infection 20 (17e23) 23 (20e24) 0.140
Chronic comorbidities
Diabetes, n (%)
Colonization 5 (14.3) 5 (50.0) 0.017 0.039 5.6 (1.09e29.03)
Infection 6 (17.1) 5 (62.6) 0.235
Hypertension, n (%)
Colonization 20 (57.1) 5 (50.0) 0.688
Infection 9 (25.7) 8 (100.0) 0.054
Coronary artery disease, n (%)
Colonization 7 (20.0) 2 (20.0) 1.000
Infection 5 (14.3) 1 (12.5) 0.319
Chronic kidney disease, n (%)
Colonization 9 (25.7) 1 (10.0) 0.292
Infection 1 (2.9) 3 (37.5) 0.091
Liver cirrhosis, n (%)
Colonization 0 (0.0) 0 (0.0) e
Infection 0 (0.0) 1 (12.5) 0.333
COPD, n (%)
Colonization 6 (17.1) 2 (20.0) 0.835
Infection 4 (11.4) 0 (0.0) 0.171
Cerebral vascular accident, n (%)
Colonization 11 (31.4) 5 (50.0) 0.279
Infection 2 (5.7) 3 (37.5) 0.186
Cancer, n (%)
Colonization 9 (25.7) 2 (20.0) 0.711
Infection 2 (5.7) 1 (12.5) 0.751
Past histories
Cigarette smoking, n (%)
Colonization 9 (25.7) 2 (20.0) 0.711
Infection 1 (2.9) 0 (0.0) 0.667
Alcohol drinking, n (%)
Colonization 4 (11.4) 2 (20.0) 0.402
Infection 0 (0.0) 0 (0.0) e
Pulmonary TB history, n (%)
Colonization 5 (14.3) 0 (0.0) 0.328
Infection 1 (2.9) 0 (0.0) 0.667
Laboratory profiles
WBC, median (IQR)
Colonization 10,500 (6875e12,675) 11,400 (8075e17,050) 0.662
Infection 10,100 (8600e15,600) 12,350 (9750e19,700) 0.133
Hematocrit, mean (SD)
Colonization 30.3 (4.5) 30.7 (5.1) 0.764
Infection 30.3 (5.2) 30.9 (5.2) 0.796
Creatine, median (IQR)
Colonization 0.86 (0.60e1.82) 0.82 (0.46e2.73) 0.754
Infection 0.81 (0.56e1.81) 1.60 (0.35e4.08) 0.830
C-reactive protein, median (IQR)
Colonization 67.0 (23.0e139.5) 44.6 (29.1e104.7) 0.548
Infection 54.1 (37.4e148.4) 153.1 (56.8e222.0) 0.159
Clinical profiles
Blood pH, mean (SD)
Colonization 7.44 (0.06) 7.45 (0.12) 0.118
Infection 7.44 (0.07) 7.39 (0.07) 0.118
(continued on next page)
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Table 3 e (continued )
Variables Without recurrence
(n ¼ 35, 16)a
Recurrence
(n ¼ 10, 8)b
Univariate
analysis P
Multivariate
analysis P
OR (95% CI)d
FiO2 (%), median (IQR)
Colonization 35 (30e40) 40 (35e40) 0.261
Infection 35 (37.5e40) 40 (32.5e47.5) 0.551
PaO2/FiO2 < 200, n (%)
Colonization 2 (5.7) 3 (30.0) 0.031
Infection 3 (8.6) 2 (25.0) 0.593
Glasgow Coma Scale, median (IQR)
Colonization 10 (7e11) 7.25 (8.5e10.25) 0.631
Infection 8.5 (7e10) 11 (6.75e11) 0.188
Shock, n (%)
Colonization 8 (22.9) 2 (20.0) 0.848
Infection 2 (5.7) 1 (12.5) 0.751
Radiologic characteristics
Localized patch, n (%)
Colonization 18 (51.4) 8 (80.0) 0.297
Infection 8 (50) 8 (100) 0.022c
Treatment
Days from culture positive to antibiotics initiation, median (IQR)
Colonization 3 (2e6) 3 (2e4) 0.429
Infection 3 (2e5) 4 (3e4) 0.432
Antibiotics duration, median (IQR)
Colonization 11 (9e14) 9.5 (6.75e11.25) 0.099
Infection 11 (9e20) 14 (7e22) 0.877
Abbreviations: MDR-AB: Multidrug-resistant Acinetobacter baumannii; SD: Standard deviation; IQR: Interquartile range; APACHE II: Acute Phys-
iology and Chronic Health Evaluation scoring system; COPD: Chronic obstructive pulmonary disease; TB: Tuberculosis; WBC: White blood cell;
FiO2: Fraction of inspired oxygen; OR: Odds ratio; CI: Confidence interval.
a The number of “colonization group” and “infection group” in without recurrence section is 35 and 16, respectively.
b The number of “colonization group” and “infection group” in recurrence section is 10 and 8, respectively.
c Localized patch is the only risk factor of recurrence in the infection group; however, there is no variation in the recurrence group. More
subjects for the infection group are required to clarify this impact.
d The ORs are obtained from the univariate analysis, instead of multiple logistic regression.
b i om e d i c a l j o u r n a l 3 9 ( 2 0 1 6 ) 1 3 0e1 3 8136patient group. The localized patches probably represent a
higher pathogen burden, and the pathogen may not be fully
eliminated under inadequate treatment course or drug con-
centration. For the infection group, localized patch (univariate
analysis, p ¼ 0.022) is the only risk factor of recurrence in the
infection group. However, there is no variation in the recur-
rence group. More subjects for the infection group are
required to clarify this impact.
Diabetes and ARDS (PaO2/FiO2 < 200) shows a significant
difference in univariate analysis in the “colonization group”
for MDR-AB recurrence, but diabetes mellitus becomes the
only independent risk factor after multivariate analysis. A
certain relationship between diabetes and ARDS may account
for the result, and diabetes is the dominate factor while
comparing with ARDS. In fact, the relationship has been
widely discussed; some people believe the intersection ofTable 4 e Comparing the initial antibiotics selection in each gr
Variables Without eradic
Colonization group
Aerosolized colistin only (n ¼ 64) 19 (29.7
Infection group
Intravenous colistin (n ¼ 1) 1 (100
Tigecycline (n ¼ 9) 7 (77.8
Sulbactam (n ¼ 4) 0 (0.0)
Aerosolized colistin þ tigecycline (n ¼ 23) 9 (39.1
Aerosolized colistin þ sulbactam (n ¼ 5) 1 (20.0hyperglycemia, metabolic abnormalities, inflammation, or
therapeutic agents contributing to the relationship [26].
Owing to the finding of diabetes influence on MDR-AB
eradication and recurrence, we tried to discover the relation-
ship between MDR-AB eradication and sugar control. HbA1c
was chosen as the standard to characterize sugar control,
because we think HbA1c is objective and quantitative. The
ROC curve made a cut-point of HbA1c ¼ 7.0 (AUC: 0.73), but
p > 0.05 between HbA1c < 7.0 and HbA1c > 7.0. We did not
disclaim the importance of diabetes control; on the other
hand, more case numbers are required to confirm its influ-
ence. Another possible explanation is that HbA1c can only
represent the sugar control in the past 3 months rather than
the “current sugar control status” during antimicrobial ther-
apy. However, it is difficult to characterize current sugar
control status; it is also greatly affected by the operator of theoup.
ation, n (%) Eradication, n (%) Recurrence
) 45 (70.3) 10
.0) 0 (0.0) e
) 2 (22.2) 1
4 (100.0) 1
) 14 (60.9) 6
) 4 (80.0) 0
b i om e d i c a l j o u r n a l 3 9 ( 2 0 1 6 ) 1 3 0e1 3 8 137fingertip testing (e.g., insufficiency time between the food
intake and fingertip testing).
The treatment on MDR-AB-colonized patients is contro-
versial, and some physicians even advocate that antibiotics
are not necessary in colonized cases. In our experience, MDR-
AB colonization makes a huge medical waste since they may
cause another outbreak if the lack of strict hand washing
policies. Besides these, patients are often rejected from local
chronic facilities and thus seriously reduced the bed avail-
ability in medical centers. In our opinion, the information for
MDR-AB colonization in our study still provides certain use in
practice if intensive MDR-AB eradication is demanded by
clinical physicians.
To the best of our knowledge, our research is the first one to
study the MDR-AB recurrence. A more aggressive disease
control policy, prolonged duration of contact precautions, or
meticulous environmental decontamination is considered on
those infected by MDR-AB. Besides, we propose a higher
standard eradication criteria and intensive pulmonary secre-
tion culture check-up on these patients to prevent a possible
cross-infection to other hosts.
There are limitations to this study. First, we excluded pa-
tients without antibiotics treatment in our study since they
are usually identified to be MDR-AB-colonized. This group did
not receive intensive pulmonary secretion culturing exam or
laboratory exams and will easily cause bias. We, therefore,
miss the information of MDR-AB recurrence in spontaneously
MDR-AB-eradicated patients. A well-designed prospective
study in the future may be required to solve the situation.
Second, we do not perform molecular examination due to
equipment limitation and failed to distinguish the recurrence
MDR-AB from the origin strain or cross-infected strain. Last,
most people enrolled in our study received aerosolized colistin
rather than intravenous colistin; it is because the high pro-
portion of old age or CKD patients in RCC. Concerning the
possibility of colistin-related kidney injury [27], physicians
seldom prescribe intravenous colistin unless MDR-AB
bacteremia or high disease severity. However, this concept is
challenged nowadays since some debate that colistin give a
relatively high clinical cure rates and over-estimated in the
incidence of kidney injury [28].Conclusion
Diabetes mellitus and ARDS are risk factors to affect MDR-AB
eradication. For the overall MDR-AB-eradicated patients, dia-
betesmellitus and localized pneumonia patch are the two risk
factors. As regards to the MDR-AB colonization group, dia-
betes mellitus is the only independent factor to increase the
recurrence rate. The localized patch in the infection group and
the influence of HbA1c require further investigation. Recog-
nizing the risk factors contributes to early detection of disease
recurrence and preventing the possible cross-contamination
to other hosts.Source of support
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